TY - JOUR
T1 - SGLT 2 inhibitors in Type 1 diabetes
AU - Stougaard, Elisabeth Buur
AU - Amadid, Hanan
AU - Søndergaard, Esben
AU - Jørgensen, Marit Eika
AU - Persson, Frederik
AU - Rossing, Peter
PY - 2020/8/24
Y1 - 2020/8/24
N2 - The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been approved for the treatment of Type 1 diabetes (T1D) with significant reductions in HbA1c, weight, total daily insulin dose and significant increase in time in range without an increased risk of hypoglycaemia. The use of SGLT2i in T1D has, however, shown a significant increase from 1,9% to 4,0% in the risk of diabetic ketoacidosis (DKA), which may present as euglycaemic DKA. In this review we therefore find it important to know, that DKA may present with normal/near-normal blood glucose levels, if the patient is treated with an SGLT2i.
AB - The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been approved for the treatment of Type 1 diabetes (T1D) with significant reductions in HbA1c, weight, total daily insulin dose and significant increase in time in range without an increased risk of hypoglycaemia. The use of SGLT2i in T1D has, however, shown a significant increase from 1,9% to 4,0% in the risk of diabetic ketoacidosis (DKA), which may present as euglycaemic DKA. In this review we therefore find it important to know, that DKA may present with normal/near-normal blood glucose levels, if the patient is treated with an SGLT2i.
UR - http://www.scopus.com/inward/record.url?scp=85089794146&partnerID=8YFLogxK
M3 - Journal article
C2 - 32829747
AN - SCOPUS:85089794146
SN - 0041-5782
VL - 182
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
IS - 35
ER -